Clinical trial · Interventional
Rational Approach to a Unilateral Pleural Effusion2
Rational Approach to Unilateral Pleural Effusion in Patients Suspected of Malignancy. Efficacy, Pain, Quality of Life, and Economy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Patient inclusion cannot be reached within timelimits
Summary
Brief summary (as posted)
Recurrent unilateral, non-infectious pleural exudate is suspicious for primary or secondary pleural malignancy. Both conditions are associated with 5-year survival of 10%. Work-up is difficult, as the pleural surface is large and \<33% of pleural malignancies shed malignant cells to the pleural fluid. Even so, additional tissue biopsies are needed for establishing mutation status for targeted therapies. Optimal imaging to guide tissue sampling is pivotal. PET-CT has higher sensitivity than conventional CT for detecting malignant lesions \>10mm. However, no randomised trial has investigated differences in diagnostic accuracy, time-to-diagnosis, or economics. Falsely PET-positive lesions in e.g. colon however, lead to more derived tests than do CT alone. Gold standard for pleural tissue sampling is the surgical (VATS) thoracoscopy, allowing direct visual guiding of tissue sampling from all pleural surfaces. Yet, globally the medical (pleuroscopy) thoracoscopy is more widely used: cheaper, outpatient procedure, but allows only sampling from the parietal pleura. To date, no randomised studies have compared medical and surgical thoracoscopy concerning diagnostic hit rates, adverse events, or economics. The investigators will perform two randomized studies to investigate whether 1. PET/CT is comparable to CT alone 2. VATS is comparable to pleuroscopy concerning hit rate, total investigations performed, time-to-diagnosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Contrast-enhanced CT | Device | — | UNRESOLVED |
| PET-CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- CE-CT scanning
- description
- Contrast-enhanced CT scan of the thorax and abdomen.
- interventionNames
- Device: Contrast-enhanced CT
- type
- ACTIVE_COMPARATOR
- label
- PET-CT scanning
- description
- Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.
- interventionNames
- Device: PET-CT
Primary outcomes (1)
- measure
- Number of diagnostic thoracoscopies (either MT or VATS)
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with recurrent pleural effusion of unknown origin after a first pleural tap according to BTS guidelines. 2. Indication for thoracoscopy according to BTS guidelines. 3. Patients accept further investigation according to Danish and BTS guidelines. 4. Have received oral and written consent and agreed. 5. At the time of inclusion, above 18 years of age. Exclusion Criteria: 1. Female patients: pregnancy or breastfeeding. 2. Lack of language comprehension. 3. Legally incompetent patients. 4. Life expectancy less than 3 month. 5. Contraindications to pleural tissue sampling.
References
Publications (0)
Data not yet available